Request availability and a quotation for your required quantity and destination.
| Product | Sildenafil 50 mg – Penegra Tablet |
|---|---|
| Categories | Erectile Dysfunction, Sildenafil Citrate |
| Availability | Confirmed on enquiry |
Product listing is not a recommendation to use this medicine. Prescription and destination requirements apply where relevant.
Composition: Sildenafil 50 mg (as sildenafil citrate, subject to original packaging verification). Dosage form: Oral tablet. Therapeutic class: Phosphodiesterase type 5 (PDE5) inhibitor. Prescription: Required where regulated.
Sildenafil is prescribed for erectile dysfunction in appropriate adults. It supports blood flow during sexual stimulation; it is not an aphrodisiac or protection against sexually transmitted infections. Clinical suitability depends on a health assessment.
Do not use sildenafil together with nitrates or riociguat because severe low blood pressure may result. Discuss heart disease, low blood pressure, liver or kidney conditions, alpha-blockers and all other medicines with a clinician. Seek emergency assistance for chest pain, sudden vision or hearing loss, or a prolonged erection lasting four hours or more.
Explore other Sildenafil brands and strengths · Explore erectile dysfunction product catalogue
It is marketed as sildenafil 50 mg. Always confirm the exact product label and batch.
Prescription and import requirements vary by destination; a qualified clinician should assess suitability.
No. This combination can cause potentially life-threatening hypotension.
Do not combine PDE5 inhibitors without explicit specialist guidance.
Headache, flushing, indigestion, congestion and dizziness may occur. Seek urgent help for severe symptoms.
Cureiva enquiry: Catalogue information only. Supply depends on authentic batch verification, prescription requirements, product availability and local regulations.
Related patient guide: Read sildenafil versus tadalafil: timing, duration and safety. This link is educational, not a dosing recommendation. A prescriber should review suitability, and PDE5 inhibitors must not be combined with nitrate medicines.